FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer

BACKGROUND: The chemotherapy triplet FOLFOXIRI combined to the anti-VEGF antibody bevacizumab is an option in selected patients with metastatic colorectal cancer. In this setting, RAS-mutated metastatic colorectal cancer do not benefit the same from treatment than RAS-wildtype metastatic colorectal...

Descripción completa

Detalles Bibliográficos
Autores principales: Adenis, Antoine, Mazard, Thibault, Fraisse, Julien, Chalbos, Patrick, Pastor, Brice, Evesque, Ludovic, Ghiringhelli, Francois, Mollevi, Caroline, Delaine, Stéphanie, Ychou, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130420/
https://www.ncbi.nlm.nih.gov/pubmed/34001059
http://dx.doi.org/10.1186/s12885-021-08312-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130420/
https://www.ncbi.nlm.nih.gov/pubmed/34001059
http://dx.doi.org/10.1186/s12885-021-08312-7

Ejemplares similares